Tolerance and Efficacy Study of Second-line Surgery After Percutaneous Needle Aponeurotomy for Dupuytren's Disease.

Last updated: November 15, 2019
Sponsor: Ramsay Générale de Santé
Overall Status: Active - Recruiting

Phase

N/A

Condition

Pressure Ulcer

Dupuytren's Disease

Surgery

Treatment

N/A

Clinical Study ID

NCT04164953
2017-A03363-50
  • Ages > 18
  • All Genders

Study Summary

As part of a graduated medical-surgical strategy, and in our practice, surgery for Dupuytren's disease appears as a second-line treatment indicated in a situation of failure after treatment with percutaneous needle aponeurotomy.The results of second-line surgery in terms of safety and efficacy have not been specifically evaluated in patients who underwent failed percutaneous needle aponeurotomy. This evaluation nevertheless appears necessary for the validation of a medical-surgical strategy during Dupuytren's disease.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient with Dupuytren's disease previously treated by percutaneous needleaponeurotomy and not satisfied after a delay of at least one month in regards to atleast one of the treated segments (are you satisfied? response no)

  • Keeping a flexum > 20°

  • At least 18 years old

  • Informed about the study and having given their informed and written consent forparticipation

  • Registered with a social security scheme or the CMU (beneficiary or entitled)

  • having had a medical examination confirming the surgical indication (the results ofwhich were communicated to them).

Exclusion

Exclusion Criteria:

  • Cognitive disorders deemed incompatible with participation in the trial by theresearcher (inability to understand the information, give informed consent or followthe required assessments)

  • Pregnancy in progress confirmed by interview

  • language barrier that would prevent the achievement of a reliable evaluation

  • Superficial or deep palmo-digital infection or inflammation

  • Ruptured tendon of the flexor digitorum

  • Contraindication to surgery or anaesthesia

  • Participation of the patient in another clinical study in progress.

  • Protected adults under guardianship, trusteeship or other legal protection, deprivedof liberty by judicial or administrative decision, Pregnant, lactating or parturientwomen, Hospitalised without consent.

9- Patient who has already undergone the surgical procedure under study on one of thetwo hands in the last 12 months or patient requiring surgery for the second hand inthe next 14 months.

Study Design

Total Participants: 50
Study Start date:
April 12, 2019
Estimated Completion Date:
June 30, 2021

Study Description

Dupuytren's disease is characterised by retractile fibrosis of the superficial palmar aponeurosis that can result in irreversible flexing of the fingers and long-term disability. The treatment of Dupuytren's disease, whether medical or surgical, remains symptomatic. It is based in Europe on percutaneous needle aponeurotomy and surgical aponeurectomy. Its objectives are the reduction of the deformity of the fingers in flexum, and that of the incapacity that generates the illness. Percutaneous needle aponeurotomy for Dupuytren's disease was developed by Jean-Luc Lermusiaux in 1972 in the Rheumatology Department of the Lariboisière Hospital in Paris. Its efficiency, its tolerance, its simplicity, its low cost and the possibility of repeating it make it a benchmark treatment. Percutaneous needle aponeurotomy is, for many, if the existence of this technique is known and understood, the first-line treatment of Dupuytren's disease.

As part of a graduated medical-surgical strategy, and in our practice, surgery for Dupuytren's disease appears as a second-line treatment indicated in a situation of failure after treatment with percutaneous needle aponeurotomy. The safety and efficacy of the surgery was evaluated in the context of a first-line treatment of Dupuytren's disease. The results of second-line surgery in terms of safety and efficacy have not been specifically evaluated in patients who underwent failed percutaneous needle aponeurotomy. This evaluation nevertheless appears necessary for the validation of a medical-surgical strategy during Dupuytren's disease.

Connect with a study center

  • Clinic Jouvenet

    Paris, IDF 75016
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.